Luffa Cylindrica

Total Page:16

File Type:pdf, Size:1020Kb

Luffa Cylindrica Metadata of the article that will be visualized in OnlineFirst 1 Article Title Luffa cylindrica: a promising herbal treatment in progesterone induced obesity in mice 2 Article Sub- Title 3 Article Copyright - Springer Nature Switzerland AG 2021 Year (This will be the copyright line in the final PDF) 4 Journal Name Journal of Diabetes & Metabolic Disorders 5 Family Name Biradar 6 Particle 7 Given Name Prakash Rajshekhar 8 Suffix 9 Corresponding Organization KLE Academy of Higher Education and Research Author (KAHER) 10 Division Department of Pharmacology and Toxicology, KLE College of Pharmacy, Belagavi 11 Address Belagavi 590010, India 12 e-mail [email protected] 13 Family Name Wilnellia 14 Particle 15 Given Name D’silva Wilnoska 16 Suffix 17 Author Organization KLE Academy of Higher Education and Research (KAHER) 18 Division Department of Pharmacology and Toxicology, KLE College of Pharmacy, Belagavi 19 Address Belagavi 590010, India 20 e-mail 21 Author Family Name Patil 22 Particle 23 Given Name Ashiwini 24 Suffix 25 Organization KLE Academy of Higher Education and Research (KAHER) 26 Division Department of Pharmacology and Toxicology, KLE College of Pharmacy, Belagavi 27 Address Belagavi 590010, India 28 e-mail 29 Received 31 August 2020 30 Schedule Revised 31 Accepted 20 January 2021 32 Abstract Objective: The present study investigates the anti-obesity activity of Luffa cylindrica in progesterone induced obesity model. Method: Swiss albino mice were grouped into 7 (n = 6). Obesity was induced by administration of progesterone (10 mg/kg s.c.) for 28 days.Normal group received ad libitum and water. Disease control, positive control and treatment groups received progesterone (10 mg/kgs.c.). Further positive control group received Orlistat (10 mg/kg p.o). Treatment groups received hydro-alcoholic and fractionation extract of Luffa cylindrica at doses 400, 200, 100 mg/kg b.w. Food and water intake were recorded daily, Body weight, BMI and blood glucose were checked weekly. On completion of the study, animals were sacrificed and blood serum being utilized to accesses in vitro the estimate the various biochemical parameters. Serotonin levels and antioxidant biomarkers were also estimated. Histopathology of liver and adipose tissue was studied. Result: After the 28 days of treatment with plant extract and fraction, it was observed to improve the progestrogen-induced obesity by improving BMI, body weight, brain serotionin, locomotor activity, blood glucose level, anti- oxidant biomarkers, and lipid profile. Conclusion: After assimilating the In vivo and in vitro studies Luffa cylindrical extract highlighted the antilipidemic, anti-hyperglycaemic, antioxidant potential in hormone-induced obesity. 33 Keywords separated Luffa cylindrica - Obesity - Progesterone - Serotonin - Orlistat by ' - ' 34 Foot note Springer Nature remains neutral with regard to jurisdictional claims in information published maps and institutional affiliations. JrnlID 40200_ArtID 749_Proof# 1 - 31/01/2021 Journal of Diabetes & Metabolic Disorders https://doi.org/10.1007/s40200-021-00749-8 1 34 RESEARCH ARTICLE 2 5 6 Luffa cylindrica: a promising herbal treatment in progesterone 7 induced obesity in mice 8 D’silva Wilnoska Wilnellia1 & Prakash Rajshekhar Biradar 1 & Ashiwini Patil1 9 10 Received: 31 August 2020 /Accepted: 20 January 2021 11 # Springer Nature Switzerland AG 2021 12 Abstract 13 Objective The present study investigates the anti-obesity activity of Luffa cylindrica in progesterone induced obesity model. 14 Method Swiss albino mice were grouped into 7 (n = 6). Obesity was induced by administrationOF of progesterone (10 mg/kg s.c.) 15 for 28 days.Normal group received ad libitum and water. Disease control, positive control and treatment groups received 16 progesterone (10 mg/kgs.c.). Further positive control group received Orlistat (10 mg/kg p.o). Treatment groups received 17 hydro-alcoholic and fractionation extract of Luffa cylindrica at doses 400, 200, 100 mg/kg b.w. Food and water intake were 18 recorded daily, Body weight, BMI and blood glucose were checked weekly. On completion of the study, animals were sacrificed 19 and blood serum being utilized to accesses in vitro the estimate the variousPRO biochemical parameters. Serotonin levels and 20 antioxidant biomarkers were also estimated. Histopathology of liver and adipose tissue was studied. 21 Result After the 28 days of treatment with plant extract and fraction, itD was observed to improve the progestrogen-induced 22 obesity by improving BMI, body weight, brain serotionin, locomotorE activity, blood glucose level, anti-oxidant biomarkers, and 23 lipid profile. 24 Conclusion After assimilating the In vivo and in vitro studies Luffa cylindrical extract highlighted the antilipidemic, anti- 25 hyperglycaemic, antioxidant potential in hormone-induced obesity. 26 Keywords Luffa cylindrica . Obesity . Progesterone . Serotonin . Orlistat 27 28 ORRECT 29 Introduction C prevalence reports adjusted for age, at least 30% of males and 40 35% of females were noted to be obese [3, 4]. 41 30 Obesity occurs as a result of a disparity between energy ex- BMI, which is a value derived by calculating the ratio of 42 31 penditure and energy intakeUN which leads to an increase in the body weight in kilograms to the square of the height in 43 32 circulatory lipid concentration and enlargement of fat mass. meters, is used to define normal weight, overweight and obe- 44 33 The aetiological factors of obesity include fluctuations in the sity. Normal: BMI 18.5-24.9 kg/m2, overweight: BMI 25-29.9 45 34 circulatory levels of certain hormones, such as leptin, insulin, kg/m2, class I obese: BMI 30-34.9 kg/m2, class II obese: BMI 46 35 sex hormones and growth hormones that majorly influence 35-39.9 kg/m2, and class III obese: BMI 40 or greater kg/m2 47 36 appetite, body fat distribution, metabolism, storage and also [morbidly obese] [5, 6]. 48 37 influenced by various lifestyle factors [1, 2]. The ubiquity of Obesity is a common risk factor for multiple comorbidity 49 38 obesity is noted to have increased multifold in the preceding conditions such as cardiovascular diseases, hypertension, dys- 50 39 few decades. According to a recent estimate of global obesity lipidemia, type-2 diabetes mellitus and insulin resistance. The 51 prevalence of these comorbidities is directly proportionate to 52 the degree of obesity [7–9]. 53 54 * Prakash Rajshekhar Biradar Amongst the hormones that modulate food intake and en- [email protected]; [email protected] ergy balance in mammals, the sex hormones estrogen and 55 progesterone are considered to have a prominent role [10]. 56 Progesterone is produced endogenously and has the primary 57 1 Department of Pharmacology and Toxicology, KLE College of 58 Pharmacy, Belagavi, KLE Academy of Higher Education and role of regulating embryogenesis, pregnancy, lactation and Q1 Research (KAHER), Belagavi 590010, India menstrual cycle [11]. The use of progesterone containing 59 JrnlID 40200_ArtID 749_Proof# 1 - 31/01/2021 J Diabetes Metab Disord 60 preparations in contraceptives and hormone replacement ther- Extraction of plant material 108 61 apy has been shown to cause hyperphagia and increased fat 62 deposition leading to substantial weight gain [12, 13]. .Some 200 gms of coarsely powdered plant material was macerated 109 63 women have been noted to develop a depressive illness due to with hydro-alcohol for seven days in the ratio of 7:3with oc- 110 64 an increase in progesterone secretion [14, 15]. Progesterone casional shaking. The macerated solute was filtered using 111 65 has been proven to induce hyperphagia by modulating sero- Whatman filter paper and the filtrate stored. With the aim of 112 66 tonergic agents [16, 17]. doing Soxhlet extraction, 100 g of marc was taken in 400 ml 113 67 Obesity has been considered to be a chronic disease of ethanol for a period of 72 hours at 40°C (flask size 400 ml). 114 68 and hence anti-obesity medications are prescribed for The solution thus obtained was then filtered. Following this, 115 69 long-term treatment which have numerous side effects the two filtrates, ie the one obtained post maceration and the 116 70 [18]. There are several herbal plants whose active compo- one obtained post Soxhlet extraction, were mixed and a con- 117 71 nents are being used in anti-obesity treatment, given their centrate prepared in the rotary evaporator. The resultant con- 118 72 safety, efficacy, cultural acceptability and a more accept- centrate was then transferred onto a Petri plate and evaporated 119 73 able side-effect profile [19, 20]. It has been reported that on a water bath. The final filtrate obtained post these proce- 120 74 movement behavior profiles across work and leisure time- dures, was stored in an air tight container and lyophilized to 121 75 use compositions are associated with obesity [21] powered extract. 122 76 reflecting the requirement of adequate balance between OF 77 work and leisure movement. Fractionation 123 78 Luffa cylindrica or Luffa aegyptiaca is a member of the 79 Cucurbitaceae family. Used over generations as an herbal Using a separating funnel, a crude extract was prepared by 124 80 remedy in different countries for the treatment of various types mixing dichloromethanePRO and citric acid 5% thoroughly. The 125 81 of diseases. The plant contains a group of phytoconstituents to aqueous layer obtained was separated and concentrated on a 126 82 include alkaloids, phenols, flavonoids, saponins, tannins, ste- Petri plateD and ammonia was added to make up the pH to 9.2. 127 83 roids, ascorbic acid, triterpenoids, and oleanolic acid render- TheE residue was again extracted with dichloromethane and 128 84 ing it an efficacious medicinal plant. Most studies have report- citric acid in the ratio of 1:1. The citric acid layer was concen- 129 85 ed that these bioactive compounds have promising effects in trated to give flavonoids and saponins. Finally, the mixture 130 86 tackling obesity by several mechanisms [22, 23].
Recommended publications
  • Lifestyle Drugs” for Men and Women
    Development of “Lifestyle Drugs” for Men and Women Armin Schultz CRS - Clinical Research Services Mannheim GmbH AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle drugs Smart drugs, Quality-of-life drugs, Vanity drugs etc. Lifestyle? Lifestyle-Drugs? Active development? Discovery by chance? AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle A lifestyle is a characteristic bundle of behaviors that makes sense to both others and oneself in a given time and place, including social relations, consumption, entertainment, and dress. The behaviors and practices within lifestyles are a mixture of habits, conventional ways of doing things, and reasoned actions „Ein Lebensstil ist [...] der regelmäßig wiederkehrende Gesamtzusammenhang der Verhaltensweisen, Interaktionen, Meinungen, Wissensbestände und bewertenden Einstellungen eines Menschen“ (Hradil 2005: 46) Different definitions in social sciences, philosophy, psychology or medicine AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle Many “subdivisions” LOHAS: “Lifestyles of Health and Sustainability“ LOVOS: “Lifestyles of Voluntary Simplicity“ SLOHAS: “Slow Lifestyles of Happiness and Sustainability” PARKOS: “Partizipative Konsumenten“ ……. ……. ……. AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle drugs Lifestyle drug is an imprecise term commonly applied to medications which treat non-life threatening and non-painful conditions such as baldness, impotence, wrinkles, or acne, without any medical relevance at all or only minor medical relevance relative to others. Desire for increase of personal well-being and quality of life It is sometimes intended as a pejorative, bearing the implication that the scarce medical research resources allocated to develop such drugs were spent frivolously when they could have been better spent researching cures for more serious medical conditions.
    [Show full text]
  • Carboxylesterases: Pharmacological Inhibition Regulated Expression and Transcriptional Involvement of Nuclear Receptors and Other Transcription Factors
    CARBOXYLESTERASES: PHARMACOLOGICAL INHIBITION REGULATED EXPRESSION AND TRANSCRIPTIONAL INVOLVEMENT OF NUCLEAR RECEPTORS AND OTHER TRANSCRIPTION FACTORS Yuanjun Shen1, Zhanquan Shi2 and Bingfang Yan2,3 Division of Pharmaceutical Sciences James L. Winkle College of Pharmacy University of Cincinnati Cincinnati, OH 45229 USA. Address Correspondence to: Dr. Bingfang Yan Division of Pharmaceutical Sciences James L. Winkle College of Pharmacy University of Cincinnati Cincinnati, OH 45229 Phone: (513) 558-6297 Fax: (513) 558-3233 E-mail: [email protected] Running Title: Regulated expression and inhibited activity of carboxylesterases FOOTNOTES 1 Current address: Pittsburgh Heart, Lung and Blood Vascular Medicine Institute, University of Pittsburgh Department of Medicine, Pittsburgh, PA 15261, USA. 2 Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45229, USA 3 To whom correspondence should be addressed. 4 This work was supported by National Institutes of Health Grants R01GM61988 and R01EB018748. 5 Abbreviation used: CAR, Constitutive androstane receptor; CES1, carboxylesterase-1; DEC1, Differentiated embryo chondrocyte-1; 5-FU: Fluorouracil; GR, Glucocorticoid receptor; IL-6, Interlekin- 6; LPS, Lipopolysaccharides; Nrf2, Nuclear factor (erythroid-derived 2)-like 2; p53, Tumor protein p53; PXR, Pregnane X receptor Carboxylesterases (CESs, E.C.3.1.1.1) constitute a large class of enzymes that determine the therapeutic efficacy and toxicity of ester/amide drugs. Without exceptions, all mammalian species studied express multiple forms of carboxylesterases. Two human carboxylesterases, CES1 and CES2, are major contributors to hydrolytic biotransformation. Recent studies have identified therapeutic agents that potently inhibit carboxylesterases-based catalysis. Some of them are reversible whereas others irreversible. The adrenergic antagonist carvedilol, for example, reversibly inhibits CES2 but this carboxylesterase is irreversibly inhibited by orlistat, a popular anti-obesity medicine.
    [Show full text]
  • Cyproterone Acetate in the Management of Polycystic Ovary Syndrome
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Journal of Rawalpindi Medical College Journal of Rawalpindi Medical College (JRMC); 2018;22(3): 262-265 Original Article Comparison of Metformin and Ethinyl Estradiol- Cyproterone Acetate in the Management of Polycystic Ovary Syndrome Sadaf Ajaib, Maimoona Ali Department of Gyanecology and Obstetrics, Military Hospital, Rawalpindi Abstract predisposition. The rudimentary quandary is in the hypothalamic pituitary axis leading to incremented Background: To compare ethinyl estradiol- LH/FSH ratio1. The cumulation of anovulation and cyproterone acetate and metformin for polycystic hyperandrogenism denotes the classic form of PCOS ovarian syndrome in terms of mean hirsutism score which exhibits the adverse metabolic phenotype of the and waist hip ratio (WHR). syndrome. Clinical and biochemical features of these Methods: A total of 120 patients (60 patients in patients may vary well-according to race, ethnicity and each group) were included in the study. Group-A the diagnostic criteria used. 2 Hyper-androgenism received metformin 500mg and group-B was given may result in acne and hirsutism. Hirsutism afflicts 5- ethinyl estradiol 35 mg as treatment of polycystic 15% of females and is a paramount denouement of ovary disease (PCOD), mean hirsuitism and waist to background hyper-androgenemia. The manifestations hip ratio was measured at 6months. Hirsuitism was of polycystic ovary syndrome depends largely on measured according to Ferriman Gallway score. obesity, which exacerbates the reproductive and Circumferences were measured with an metabolic aberrations in women tormented by PCOs. anthropometric tape over light clothing. Waist girth Further studies conclude that obesity might promote was measured at the minimum circumference the phenotypic expression of PCOS in a population at between the iliac crest and the rib cage and hip girth risk of this disease.1,2 at the maximum width and their ratio was calculated Well known risk determinants for cardiovascular as baseline and after 6 months of treatment.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0022039 A1 Schwink Et Al
    US 20120022039A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0022039 A1 Schwink et al. (43) Pub. Date: Jan. 26, 2012 (54) NOVEL SUBSTITUTED INDANES, METHOD Publication Classification FOR THE PRODUCTION THEREOF, AND USE (51) Int. Cl. THEREOF AS DRUGS A 6LX 3L/397 (2006.01) C07D 207/06 (2006.01) C07D 2L/22 (2006.01) C07D 22.3/04 (2006.01) (75) Inventors: Lothar Schwink, Frankfurt am C07D 22L/22 (2006.01) Main (DE); Siegfried Stengelin, C07C 235/54 (2006.01) Frankfurt am Main (DE); Matthias C07D 307/14 (2006.01) Gossel, Frankfurt am Main (DE); A63L/35 (2006.01) Klaus Wirth, Frankfurt am Main A6II 3/40 (2006.01) (DE) A6II 3/445 (2006.01) A6II 3/55 (2006.01) A63L/439 (2006.01) A6II 3/66 (2006.01) (73) Assignee: SANOFI, Paris (FR) A6II 3/34 (2006.01) A6IP3/10 (2006.01) A6IP3/04 (2006.01) A6IP3/06 (2006.01) (21) Appl. No.: 13/201410 A6IPL/I6 (2006.01) A6IP3/00 (2006.01) C07D 309/04 (2006.01) (52) U.S. Cl. .................... 514/210.01; 549/426: 548/578; (22) PCT Filed: Feb. 12, 2010 546/205; 540/484; 546/112:564/176; 549/494; 514/459:514/408: 514/319; 514/212.01; 514/299; 514/622:514/471 (86). PCT No.: PCT/EP2010/051796 (57) ABSTRACT The invention relates to substituted indanes and derivatives S371 (c)(1), thereof, to physiologically acceptable salts and physiologi (2), (4) Date: Oct. 4, 2011 cally functional derivatives thereof, to the production thereof, to drugs containing at least one substituted indane according (30) Foreign Application Priority Data to the invention or derivative thereof, and to the use of the Substituted indanes according to the invention and to deriva Feb.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau Et Al
    US 20150202317A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau et al. (43) Pub. Date: Jul. 23, 2015 (54) DIPEPTDE-BASED PRODRUG LINKERS Publication Classification FOR ALPHATIC AMNE-CONTAINING DRUGS (51) Int. Cl. A647/48 (2006.01) (71) Applicant: Ascendis Pharma A/S, Hellerup (DK) A638/26 (2006.01) A6M5/9 (2006.01) (72) Inventors: Harald Rau, Heidelberg (DE); Torben A 6LX3/553 (2006.01) Le?mann, Neustadt an der Weinstrasse (52) U.S. Cl. (DE) CPC ......... A61K 47/48338 (2013.01); A61 K3I/553 (2013.01); A61 K38/26 (2013.01); A61 K (21) Appl. No.: 14/674,928 47/48215 (2013.01); A61M 5/19 (2013.01) (22) Filed: Mar. 31, 2015 (57) ABSTRACT The present invention relates to a prodrug or a pharmaceuti Related U.S. Application Data cally acceptable salt thereof, comprising a drug linker conju (63) Continuation of application No. 13/574,092, filed on gate D-L, wherein D being a biologically active moiety con Oct. 15, 2012, filed as application No. PCT/EP2011/ taining an aliphatic amine group is conjugated to one or more 050821 on Jan. 21, 2011. polymeric carriers via dipeptide-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeu (30) Foreign Application Priority Data tically useful half-lives. The invention also relates to pharma ceutical compositions comprising said prodrugs and their use Jan. 22, 2010 (EP) ................................ 10 151564.1 as medicaments. US 2015/0202317 A1 Jul. 23, 2015 DIPEPTDE-BASED PRODRUG LINKERS 0007 Alternatively, the drugs may be conjugated to a car FOR ALPHATIC AMNE-CONTAINING rier through permanent covalent bonds.
    [Show full text]
  • Clinical Pharmacokinetics and Pharmacodynamics CONCEPTS and APPLICATIONS 18048 FM.Qxd 11/11/09 4:31 PM Page Iii
    18048_FM.qxd 11/11/09 4:31 PM Page i Clinical Pharmacokinetics and Pharmacodynamics CONCEPTS AND APPLICATIONS 18048_FM.qxd 11/11/09 4:31 PM Page iii FOURTH EDITION Clinical Pharmacokinetics and Pharmacodynamics Concepts and Applications Malcolm Rowland, DSc, PhD Thomas N. Tozer, PharmD, PhD Professor Emeritus Professor Emeritus School of Pharmacy and School of Pharmacy and Pharmaceutical Sciences Pharmaceutical Sciences University of Manchester University of California, San Francisco Manchester, United Kingdom Adjunct Professor of Pharmacology Skaggs School of Pharmacy and Pharmaceutical Sciences University of California San Diego With Online Simulations by Hartmut Derendorf, PhD Distinguished Professor Guenther Hochhaus, PhD Associate Professor Department of Pharmaceutics University of Florida Gainesville, Florida 18048_FM.qxd 11/11/09 4:31 PM Page iv Acquisitions Editor: David B. Troy Product Manager: Matt Hauber Marketing Manager: Allison Powell Designer: Doug Smock Compositor: Maryland Composition Inc./ASI Fourth Edition Copyright © 2011 Lippincott Williams & Wilkins, a Wolters Kluwer business 351 West Camden Street 530 Walnut Street Baltimore, MD 21201 Philadelphia, PA 19106 Printed in China All rights reserved. This book is protected by copyright. No part of this book may be reproduced or transmitted in any form or by any means, including as photocopies or scanned-in or other electronic copies, or utilized by any information storage and retrieval system without written permission from the copyright owner, except for brief quotations embodied in critical articles and reviews. Materials appearing in this book prepared by individuals as part of their official duties as U.S. government em- ployees are not covered by the above-mentioned copyright. To request permission, please contact Lippincott Williams & Wilkins at 530 Walnut Street, Philadelphia, PA 19106, via email at permis- [email protected], or via website at lww.com (products and services).
    [Show full text]
  • ( Anti-Obesity Agents ) Sibutramine Orlistat Rimonabant
    2006 17 155-162 sibutramine orlistat rimonabant ( Anti-obesity agents ) Sibutramine Orlistat Rimonabant 5 12 15 1980 1986 1996 12.4% 14.8% 15.6% 10.1% 11.1% 12.9% ( metabolic syndrome ) 1993-1996 10.5% 2000-2001 15.9% 13.7% 10.7%1 2 2-4 704 138 156 BMI mulating hormone ( -MSH ) -MSH BMI menalocortin-4 ( MC4-R ) 27kg/m2 BMI <27 POMC 24kg/m2 6 MC4-R 11-13 Prader-Willi ( leptin resistance ) 14 Albright hereditary osteodystrophy Fragile X adiponectin resistin interleukin 6 ( IL-6 ) tumor necrosis fac- tor-alpha ( TNF- ) visfatin arcuate nu- cleus neuropep- tide Y ( NPY ) agouti-related peptide ( AgRP ) Ghrelin proopiomelanocortin ghrelin ( POMC ) cocaine-and amphetamine-regulated NPY AgRP transcript ( CART ) 15 ghrelin 16,17 18 7 ghrelin Cannabinoid system cholecystokinin glucagon-like peptide 1 ( GLP-1 ) pancreatic ( receptors ) polypeptide amylin peptide YY cannabinoid receptor 1 ( CB1 ) cannabinoid re- ceptor 2 ( CB2 ) CB1 CB2 cannabinoid system 8 CB1 9 CB1 blockage CB1 blockage ( ) ( ) 10 ( leptin ) ( leptin receptor ) POMC -melanocyte-sti- 157 Sibutramine 2 15 mg sibutramine 2 12 sibutra- mine 0.3 mmol/l 1.4 mmol/l ( p=0.04 ) Sibutramine ( Reductil® ® ) sibutramine 0.3% 0.0% Sibutramine ( p<0.05 ) 1.0% sibu- serotonin norepinephrine tramine 33% 5% ( SNRI ) ( p<0.05) 5% sibutramine 19% 0% ( fat mass ) sibutramine 7 1047 1.0% 0.0%( p<0.05 ) 24 24 1.8kg 0.2kg ( p<0.001 ) 24 1.2% Sibutramine sibutramine 1 mg 2.7% 5 mg 5 mg- 3.9% 10 mg 6.1% 15 mg 30 mg 7.4% 20 mg 8.8% 30 mg 10 mg 9.4% 4 15 mg 24 19 10 mg 5 mg 12 10 mg-15 mg 3-6 1.4±0.5kg
    [Show full text]
  • INN-Nimet 1 1.4.2019 a Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum Abagovomabi Abaloparatide Abaloparatidum Abalopara
    INN-nimet Lääkealan turvallisuus- ja kehittämiskeskus Säkerhets- och utvecklingscentret för läkemedelsområdet Finnish Medicines Agency 1.4.
    [Show full text]
  • Pharmacotherapies for Obesity: Past, Current, and Future Therapies
    Hindawi Publishing Corporation Journal of Obesity Volume 2011, Article ID 179674, 18 pages doi:10.1155/2011/179674 Review Article Pharmacotherapies for Obesity: Past, Current, and Future Therapies Lisa L. Ioannides-Demos, Loretta Piccenna, and John J. McNeil Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Alfred Centre, Commercial Road, Melbourne, VIC 3004, Australia Correspondence should be addressed to Lisa L. Ioannides-Demos, [email protected] Received 4 August 2010; Accepted 24 September 2010 Academic Editor: A. Halpern Copyright © 2011 Lisa L. Ioannides-Demos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Past therapies for the treatment of obesity have typically involved pharmacological agents usually in combination with a calorie- controlled diet. This paper reviews the efficacy and safety of pharmacotherapies for obesity focusing on drugs approved for long- term therapy (orlistat), drugs approved for short-term use (amfepramone [diethylpropion], phentermine), recently withdrawn therapies (rimonabant, sibutamine) and drugs evaluated in Phase III studies (taranabant, pramlintide, lorcaserin and tesofensine and combination therapies of topiramate plus phentermine, bupropion plus naltrexone, and bupropion plus zonisamide). No current pharmacotherapy possesses the efficacy needed to produce substantial weight loss in morbidly obese patients. Meta- analyses support a significant though modest loss in bodyweight with a mean weight difference of 4.7 kg (95% CI 4.1 to 5.3 kg) for rimonabant, 4.2 kg (95% CI 3.6 to 4.8 kg) for sibutramine and 2.9 kg (95% CI 2.5 to 3.2 kg) for orlistat compared to placebo at ≥12 months.
    [Show full text]
  • Fewer Opportunties for Companies to Get Fat Off Obesity Products
    October 24, 2008 Fewer opportunties for companies to get fat off obesity products Lisa Urquhart European regulators yesterday seemingly gave with one hand and then took away with the other in the world of weight loss. An announcement that the watchdog had decided to rescind marketing approval for Sanofi- Aventis' drug Acomplia following reports of adverse psychological effects was released almost at the same time as one giving the go-ahead for over-the-counter sales of GlaxoSmithKline’s alli. The decision by the regulator to suspend sales of Acomplia in all European Union states caused shares in Sanofi-Aventis to fall 6% today to €42.97. It almost certainly spells the end for the anti-obesity treatment that failed to launch in the US following an advisory committee unanimously recommending against its approval, because of concerns over psychiatric effects. Some analysts have now completely removed the drug from their models, but the psychiatric problems that have stalked the drug had already seen many analysts heavily downgrade their sales expectations. According to historic forecasts from EvaluatePharma, 2012 sales consensus has fallen by $499m in the last 12 months to $522m, and are a long cry from the $3.9bn predicted in January 2007. Even in Europe, where the drug was approved in 27 countries, there had been reluctance to prescribe it due to those concerns. Germany turned it down for insurance cover twice this year and France placed restrictive prescription criteria on the drug and only offered to reimburse at a third of the price. The decision by the regulator could also hammer the final nail into the coffin of the cannaboid type 1 antagonist drugs for weight loss, coming only weeks after the decision by Merck & Co to abandon development of taranabant, due to psychological issues.
    [Show full text]
  • Xenical, INN-Orlistat
    SCIENTIFIC DISCUSSION This module reflects the initial scientific discussion for the approval of Xenical. This scientific discussion has been updated until 1 November 2003. For information on changes after this date please refer to module 8B. 1. Introduction Obesity is a disease characterised by an excess body fat. It is often measured by calculation of the body mass index (BMI), i.e. the body weight in kg divided by body surface area in m2. Individuals may be regarded as obese with a BMI >25-27 kg/m² (depending on age). A number of concomitant pathological processes and diseases are associated with obesity including coronary heart disease, hypertension, stroke, non-insulin dependent diabetes mellitus and certain forms of cancer. Besides changes in diet, behaviour and physical activities, obesity may be treated by surgery or pharmacological therapy. All currently available medicinal products for obesity treatment are appetite suppressants (amphetamine-like products) that act via the central nervous system (CNS). However, they may not be prescribed during longer periods than 3 months, due to the potential risk of abuse. Thus, there is a need for medicinal products that can be used in chronic treatment together with dietary and behavioural modifications. Orlistat belongs to a new class of pharmacological agents. It inhibits the action of gastrointestinal lipases and thereby impairs the metabolism of lipids in the intestinal lumen leading to a prevention of lipid absorption. Xenical is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI) greater or equal to 30 kg/m², or overweight patients (BMI > 28 kg/m²) with associated risk factors.
    [Show full text]
  • XENICAL, INN-Orlistat
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Xenical 120 mg hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each hard capsule contains 120 mg orlistat. For a full list of excipients, see 6.1. 3. PHARMACEUTICAL FORM Hard capsule. The capsule has a turquoise cap and turquoise body bearing the imprint of “XENICAL 120”. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Xenical is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI) greater or equal to 30 kg/m², or overweight patients (BMI > 28 kg/m²) with associated risk factors. Treatment with orlistat should be discontinued after 12 weeks if patients have been unable to lose at least 5 % of the body weight as measured at the start of therapy. 4.2 Posology and method of administration Adults The recommended dose of orlistat is one 120 mg capsule taken with water immediately before, during or up to one hour after each main meal. If a meal is missed or contains no fat, the dose of orlistat should be omitted. The patient should be on a nutritionally balanced, mildly hypocaloric diet that contains approximately 30 % of calories from fat. It is recommended that the diet should be rich in fruit and vegetables. The daily intake of fat, carbohydrate and protein should be distributed over three main meals. Doses of orlistat above 120 mg three times daily have not been shown to provide additional benefit. The effect of orlistat results in an increase in faecal fat as early as 24 to 48 hours after dosing.
    [Show full text]